Sylvester Comprehensive Cancer Center

  • 20210235 - Alperstein Warren

  • Investigator:
    Warren Alperstein
    RCname Email

    Coordinator:
    RCemailImg Eva Pavicic
    RCphone +1 (305) 2437846

    IRB: 20210235

    SDG: Peds
    Disease Site(s):

    Multiple

    Sponsor: Atara

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases

    Eligibility Criteria - NCT04554914 *This information has been extracted from " www.clinicaltrials.gov"

  • AGCT1531 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (305) 2437130

    IRB: 20170605

    SDG: Peds
    Disease Site(s):

    Other Female Genital,Other Male Genital,Ovary

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

    Eligibility Criteria - NCT03067181 *This information has been extracted from " www.clinicaltrials.gov"

  • ANBL 1821 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20190652

    SDG: Peds
    Disease Site(s):

    Brain and Nervous System

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed, Refractory or Progressive Neuroblastoma

    Eligibility Criteria - NCT03794349 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191014 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (305) 2437130

    IRB: 20191014

    SDG: Peds
    Disease Site(s):

    Lymphoid Leukemia,Non-Hodgkin Lymphoma

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl

    Eligibility Criteria - NCT03914625 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191175 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (305) 2437130

    IRB: 20191175

    SDG: Peds
    Disease Site(s):

    Leukemia, Other,Lymphoid Leukemia

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

    Eligibility Criteria - NCT03959085 *This information has been extracted from " www.clinicaltrials.gov"

  • APEC1621F - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (305) 2437130

    IRB: 20191254

    SDG: Peds
    Disease Site(s):

    Multiple

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

    Eligibility Criteria - NCT03213652 *This information has been extracted from " www.clinicaltrials.gov"

  • APEC1621SC - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (305) 2437130

    IRB: 20191259

    SDG: Peds
    Disease Site(s):

    Multiple

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

    Eligibility Criteria - NCT03155620 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210407 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20210407

    SDG: Peds
    Disease Site(s):

    Leukemia, Other

    Sponsor: NOVARTIS

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification fo

    Eligibility Criteria - NCT03601442 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230224 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20230224

    SDG: Peds
    Disease Site(s):

    Soft Tissue

    Sponsor: COG

    Enrolling Sites:

    Sylvester

    Title:

    A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

    Eligibility Criteria - NCT05304585 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230283 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20230283

    SDG: Peds
    Disease Site(s):

    Soft Tissue

    Sponsor: COG

    Enrolling Sites:

    Sylvester

    Title:

    A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance

    Eligibility Criteria - NCT04994132 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230304 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20230304

    SDG: Peds
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: COG

    Enrolling Sites:

    Sylvester

    Title:

    A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

    Eligibility Criteria - NCT04759586 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210234 - Dhir Aditi

  • Investigator:
    Aditi Dhir
    RCname Email

    Coordinator:
    RCemailImg Eva Pavicic
    RCphone +1 (305) 2437846

    IRB: 20210234

    SDG: Peds
    Disease Site(s):

    Soft Tissue

    Sponsor: Moffitt Cancer Center

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma

    Eligibility Criteria - NCT04388839 *This information has been extracted from " www.clinicaltrials.gov"